{
    "clinical_study": {
        "@rank": "146416", 
        "arm_group": {
            "arm_group_label": "AZD1722", 
            "arm_group_type": "Experimental", 
            "description": "Single oral dose 15 mg of [14C]AZD1722"
        }, 
        "brief_summary": {
            "textblock": "To assess the absorption, distribution, metabolism and excretion of a single dose of 14C\n      labelled AZD1722 in order to define the rates and routes of elimination of AZD1722 and if\n      formed, metabolites."
        }, 
        "brief_title": "AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteers aged \u226550 years\n\n          -  Regular daily bowel movements.\n\n          -  Have a body mass index (BMI) between 18 and 32 kg/m2 (inclusive) and weigh at least\n             50 kg and no more than 110 kg.\n\n        Exclusion Criteria:\n\n          -  History of any clinically significant disease or disorder which, in the opinion of\n             the Principal Investigator, may either put the volunteer at risk because of\n             participation in the study, or influence the results or the volunteer's ability to\n             participate in the study.\n\n          -  History or presence of GI, hepatic or renal disease including GI surgery other than\n             appendectomy or any other condition known to interfere with the ADME of drugs.\n\n          -  Loose stools (Bristol Stool Form Score of 6 or 7) \u22652 days in the past 7 days before\n             admission to the study centre\n\n          -  Use of medications that are known to affect stool consistency and/or GI motility,\n             including fibre supplements, anti-diarrheals, prokinetic drugs, enemas, probiotic\n             medications or supplements; or salt or electrolyte supplements containing sodium,\n             potassium, chloride, or bicarbonate formulations during the past 7 days before\n             admission to the study centre.\n\n          -  Volunteers exposed to radiation levels above background (eg, via X-ray examination)\n             of >5 mSv in the last year, >10 mSv over the last 5 years or a cumulative total of >1\n             mSv per year of life.\n\n          -  Participation in a previously radiolabelled study within the last 5 years"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063386", 
            "org_study_id": "D5611C00007"
        }, 
        "intervention": {
            "arm_group_label": "AZD1722", 
            "description": "Single oral dose 15 mg of [14C]AZD1722", 
            "intervention_name": "AZD1722", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, Single-centre, Open-label Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) of a Single Oral Dose of 14C-labelled AZD1722 in Healthy Male Volunteers", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of radioactive dose recovered in urine and feces", 
                "safety_issue": "No", 
                "time_frame": "Day 1: Pre-dose and up to 168 hours post-dose"
            }, 
            {
                "measure": "Total percentage of radioactive dose recovered from both urine and feces", 
                "safety_issue": "No", 
                "time_frame": "Day 1: Pre-dose and up to 168 hours post-dose"
            }, 
            {
                "measure": "Concentration of total radioactivity in blood and plasma samples", 
                "safety_issue": "No", 
                "time_frame": "Timeframe: Day 1: Predose and up to 120 hours"
            }, 
            {
                "measure": "Concentration of AZD1722 in plasma samples", 
                "safety_issue": "No", 
                "time_frame": "Timeframe: Day 1: Predose and up to 120 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063386"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety variables (adverse events, vital signs, ECGs, clinical laboratory tests)", 
            "safety_issue": "Yes", 
            "time_frame": "up to 50 days"
        }, 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}